214 related articles for article (PubMed ID: 28060891)
1. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Jauw YW; Zijlstra JM; de Jong D; Vugts DJ; Zweegman S; Hoekstra OS; van Dongen GA; Huisman MC
PLoS One; 2017; 12(1):e0169828. PubMed ID: 28060891
[TBL] [Abstract][Full Text] [Related]
2. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
3. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
4. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
[TBL] [Abstract][Full Text] [Related]
7. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.
Miyoshi H; Arakawa F; Sato K; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Ichikawa A; Ishibashi Y; Nakamura Y; Nakashima S; Niino D; Sugita Y; Ohshima K
Cancer Sci; 2012 Aug; 103(8):1567-73. PubMed ID: 22500644
[TBL] [Abstract][Full Text] [Related]
9. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
10. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
12. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
13. Immunofluorescent labeling of CD20 tumor marker with quantum dots for rapid and quantitative detection of diffuse large B-cell non-Hodgkin's lymphoma.
Shariatifar H; Hakhamaneshi MS; Abolhasani M; Ahmadi FH; Roshani D; Nikkhoo B; Abdi M; Ahmadvand D
J Cell Biochem; 2019 Mar; 120(3):4564-4572. PubMed ID: 30302797
[TBL] [Abstract][Full Text] [Related]
14. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.
Adams H; van de Garde EMW; Vugts DJ; Grutters JC; Oyen WJG; Keijsers RG
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1929-1939. PubMed ID: 36826476
[TBL] [Abstract][Full Text] [Related]
15. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
16. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma.
Natarajan A; Hackel BJ; Gambhir SS
Clin Cancer Res; 2013 Dec; 19(24):6820-9. PubMed ID: 24097872
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL.
Natarajan A; Habte F; Liu H; Sathirachinda A; Hu X; Cheng Z; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2013 Aug; 15(4):468-75. PubMed ID: 23471750
[TBL] [Abstract][Full Text] [Related]
18. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Chevallier P; Pigneux A; Robillard N; Ayari S; Guillaume T; Delaunay J; Eveillard M; Dumas PY; Lippert E; Mohty M; Leguay T
Leuk Res; 2012 Mar; 36(3):311-5. PubMed ID: 22172463
[TBL] [Abstract][Full Text] [Related]
20. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
